PMV Pharmaceuticals, Inc. financial data

Symbol
PMVP on Nasdaq
Industry
Pharmaceutical Preparations
Location
400 Alexander Park Drive, Suite 301, Princeton, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.53K % -14.4%
Debt-to-equity 11 % +2.32%
Return On Equity -29.3 % +3.14%
Return On Assets -26.4 % +3.37%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.9M shares +0.95%
Common Stock, Shares, Outstanding 51.9M shares +0.95%
Entity Public Float 81.7M USD -61%
Weighted Average Number of Shares Outstanding, Basic 51.6M shares +7.42%
Weighted Average Number of Shares Outstanding, Diluted 51.6M shares +7.42%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 58.5M USD +4.73%
General and Administrative Expense 26.9M USD +11%
Operating Income (Loss) -85.4M USD -6.63%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -74.8M USD -8.49%
Income Tax Expense (Benefit) 74K USD
Net Income (Loss) Attributable to Parent -58.7M USD +14.9%
Earnings Per Share, Basic -1.14 USD/shares +20.8%
Earnings Per Share, Diluted -1.14 USD/shares +20.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 40.9M USD +8.41%
Marketable Securities, Current 129M USD -22.2%
Cash, Cash Equivalents, and Short-term Investments 183M USD -19.8%
Assets, Current 176M USD -15.3%
Property, Plant and Equipment, Net 409K USD -96.2%
Operating Lease, Right-of-Use Asset 1.14M USD -86.4%
Other Assets, Noncurrent 235K USD +23.7%
Assets 191M USD -24.1%
Accounts Payable, Current 6.58M USD +103%
Accrued Liabilities, Current 7.44M USD -25.2%
Liabilities, Current 14.4M USD +2.43%
Operating Lease, Liability, Noncurrent 838K USD -93.3%
Liabilities 15.2M USD -42.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 139K USD -37.9%
Retained Earnings (Accumulated Deficit) -369M USD -18.9%
Stockholders' Equity Attributable to Parent 176M USD -22%
Liabilities and Equity 191M USD -24.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.2M USD -7.81%
Net Cash Provided by (Used in) Financing Activities 12K USD -90.6%
Net Cash Provided by (Used in) Investing Activities 26.2M USD -47.3%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 51.9M shares +0.95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.95M USD -71.3%
Deferred Tax Assets, Valuation Allowance 96.6M USD +3.02%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure
Deferred Tax Assets, Gross 97M USD +0.64%
Operating Lease, Liability 1.19M USD -91%
Depreciation 1.14M USD -8.99%
Payments to Acquire Property, Plant, and Equipment 594K USD +281%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58.8M USD +13.9%
Property, Plant and Equipment, Gross 1.87M USD -86.6%
Operating Lease, Liability, Current 352K USD -58.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure +139%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 285K USD -92%
Deferred Tax Assets, Operating Loss Carryforwards 49.7M USD -12.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.26M USD +2.71%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 369K USD -85.7%
Share-based Payment Arrangement, Expense 8.87M USD -28.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%